UNASSIGNED: We studied outcomes of 65 consecutive @entity1 with @entity3052 ( @entity3052 ) who underwent allogeneic hematopoietic cell transplantation (HCT). Previously published scores of HCT-CI, CIBMTR, EBMT and Comorbidity-age index were also evaluated. Median follow-up of survivors was 72 months (range 16-204). At 2 years, @entity1349 ( @entity1349 ) was 34% (95% confidence interval (CI) 23-45). Nineteen @entity1 (29%) had @entity3203 ( @entity3203 ). @entity1 with @entity3203 had an @entity1349 of 21% (95% CI 7-41) at 2 years. Abnormal adverse cytogenetics, unrelated donor, bone marrow graft and CIBMTR score were significant risk factors for @entity1349 on univariate analysis. On multivariate analysis, abnormal adverse cytogenetics (hazard ratio (HR) 2.7; 95% CI 1.02-7.2; P-value=0.02) and unrelated donor (HR 2.7; 95% CI 1.5-5.0; P-value=0.0013) were independent factors for survival. Non-relapse mortality (NRM) at 2 years was 31% (95% CI 15-47). Donor type was the only factor that was significant for NRM with matched related donors having an NRM of 20% (95% CI 0-42) whereas unrelated donors had NRM of 60% (95% CI 40-80; P-value=0.0007). In conclusion, @entity1 with @entity3052 have poor @entity1349 . Unrelated donor is a significant risk factor for both higher NRM and decreased @entity1349 . Cytogenetics are predictive for @entity1349 .Bone Marrow Transplantation advance online publication, 29 June 2015; doi:10.1038/bmt.2015.151.

Outcomes of XXXX with therapy-related @entity3052 /myelodysplastic syndrome ( @entity3052 ) following hematopoietic cell transplantation.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3203 :: ('MESH:D059786', 'Disease') :: ['MK', 'monosomal karyotype'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['therapy-related AML/myelodyplastic syndrome', 't-AML/MDS']
@entity1 :: (9606,Species) :: ['patients']
